While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Trulicity Sales Alliance Deal to Expire by 2022-End: Lilly Japan/Sumitomo
August 4, 2022
-
BUSINESS Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
-
REGULATORY Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
-
REGULATORY Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
-
BUSINESS Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
-
REGULATORY KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
-
REGULATORY New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
-
BUSINESS Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
-
BUSINESS Mochida to Quit Filgrastim Biosimilar as Repeated Price Cuts Made It Unprofitable
July 28, 2022
-
BUSINESS GSK Japan Foresees 5% Annual Growth by 2026: President Lirette
July 28, 2022
-
BUSINESS Horizon Japan Eager for Solo Sales of Its 1st Product as Tepezza Trial Likely to Wrap Up Next Year
July 27, 2022
-
ORGANIZATION Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
-
ORGANIZATION JPMA Delays Announcement of Drug Pricing Proposal
July 27, 2022
-
BUSINESS BMS Has High Hopes on Eliquis Follow-Up with Less Bleeding Risks as Patent Loss Looms
July 26, 2022
-
REGULATORY Japan Confirms 1st Monkeypox Case
July 26, 2022
-
COMMENTARY Govt Should Examine Challenges with Emergency Approval Scheme Exposed by Shionogi Pill Review
July 25, 2022
-
REGULATORY KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
July 25, 2022
-
BUSINESS Keytruda, Opdivo, Tagrisso Breach 100 Billion Yen Sales Mark in FY2021: Tally
July 22, 2022
-
BUSINESS Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
July 22, 2022
-
REGULATORY Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…